Gait and Bone Health in SMA

Conditions

• Ambulatory Spinal Muscular Atrophy
• Spinal Muscular Atrophy Type 3

Eligibility Criteria

Sex

ALL

Age

8 Years - 50 Years

Healthy Volunteers

Not accepted

Study Details

The objective of this study is to understand how spatiotemporal and kinetic gait parameters are associated with bone health in pwSMA who are receiving DMT. We hypothesize that gait parameters are associated with BMD and can determine fracture risk in pwSMA. This is an observational study that involves one in-clinic visit (approximately 3 hours) with remote follow-up visits (approximately 15 minutes) every 3 months for 1 year to collect fracture and medical history. Each of the assessments included in this study are non-interventional and are not intended as a treatment nor are they at the level of standard of care.

Key Dates

Start date

Mar 5, 2026

Status verified

Mar 2026

Primary completion

Jun 30, 2027

Completion

Jun 30, 2027

Study Design

Enrollment

22 participants (estimated)

Arms

• Arm: Spinal Muscular Atrophy
  Ambulatory children and adults at least 8 years old by the time of enrollment with genetically confirmed SMA.

Primary Outcome Measure

Dual X-Ray Absorptiometry (DXA) [ Time Frame: Baseline ]

Central Contacts

• Cara Kanner, PT, DPT, EdD
  516-581-8150
  [email protected]

Locations (1)

Find similar trials in New York, NY

Related Studies

• Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
  Recruiting · Columbia University · Palo Alto, California
• A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
  PHASE2 · Recruiting · Scholar Rock, Inc. · Phoenix, Arizona